In an effort to develop an improved blood test for early detection of ovarian cancer, a rigorous landmark validation study of 49 potential markers shows that blood levels of CA-125 protein remain the best bet.
In an effort to develop an improved blood test for early detection of ovarian cancer, a rigorous landmark validation study of 49 potential markers shows that blood levels of CA-125 protein remain the best bet.
Researchers from Brigham and Women's Hospital, Boston, Massachusetts, included phase II specimens taken at diagnosis from 180 symptomatic women with ovarian cancer from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and from 660 benign disease or general population controls. The researchers found that none of the markers investigated outperformed CA-125. Even panels of markers added little value to CA-125 alone.
After CA-125, top-performing markers on the phase II specimens were HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% and specificity ranging from 0.73 to 0.40. Except for transthyretin, all the markers had similar or better sensitivity when used on phase III specimens that were drawn within 6 months of diagnosis. Performance of all markers declined in phase III specimens obtained more than 6 months from diagnosis. Researchers say the optimal marker would detect a tumor signal more than 6 months prior to diagnosis, but even CA-125 has its strongest signal within the 6-month window.
Some researchers believe that a rise in blood levels of markers over time may be used for early detection, hypothesizing that each woman has an individual baseline level for each marker, and that 1 or more of these markers rises above that baseline when she develops ovarian cancer. Detected rises then can be followed with transvaginal ultrasound for verification of disease.
Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4(3):365-374.
Multicomponent intervention boosts quality of life in overactive bladder patients
March 15th 2024A recent study reveals the efficacy of a cognitive behavior therapy program, showcasing significant improvements in health-related quality of life among women grappling with moderate to severe overactive bladder.
Read More
Optimizing pain management post urogynecologic surgery with restrictive opioid protocol
March 14th 2024A recent study suggests that restrictive opioid prescribing protocols post-urogynecologic surgery are as effective as standard protocols, emphasizing the importance of multimodal analgesia and outpatient follow-up for patient satisfaction.
Read More
Study finds no increased stress urinary incontinence recurrence risk from childbirth
March 11th 2024A recent meta-analysis challenged common clinical assumptions, finding no increased risk of stress urinary incontinence recurrence or need for reoperation after subsequent pregnancy and childbirth following a midurethral sling procedure.
Read More
Cefepime–Taniborbactam outperforms meropenem in treating complicated UTI
February 15th 2024A recent study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.
Read More